Nuevocor

Executive Summary

Nuevocor is a Singapore-based biotech developing first-in-class gene therapies for rare, untreatable cardiomyopathies. The company’s lead candidate, NVC-001, is an AAV-based therapy designed to restore nuclear envelope integrity in patients with LMNA-related dilated cardiomyopathy (LMNA-DCM), a progressive and fatal genetic heart disease with no approved treatments. Nuevocor leverages its proprietary PrOSIA platform, which targets mechanobiology pathways to correct cellular defects caused by LMNA mutations. Currently in Phase 1 clinical trials, NVC-001 aims to halt disease progression and improve cardiac function. The company’s scientific approach is anchored in a deep understanding of nuclear envelope biology and has shown promise in preclinical models. With a strong intellectual property portfolio and a clear focus on a well-defined patient population, Nuevocor represents an innovative approach to addressing a significant unmet medical need. The initial Phase 1 data are expected to provide crucial proof-of-mechanism and safety evidence, positioning the company for potential partnerships or further development. Given the high unmet need and the novelty of the approach, Nuevocor has attracted attention from specialist investors and is well-positioned in the competitive landscape for gene therapies in cardiovascular diseases.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 initial safety and efficacy data readout for NVC-00170% success
• Q4 2026Potential partnership or licensing deal for NVC-001 or platform50% success
• H1 2027Regulatory progress or IND expansion into additional indications40% success